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ABSTRACT
Arginine vasopressin (AVP) has a key role in osmoregulation by facilitating water transport in the collecting duct.
Recentevidencesuggests thatAVPmayhaveadditionaleffectsonrenal functionandfavorcystgrowth inpolycystic
kidney disease.Whether AVP also affects kidney structure in the general population is unknown.We analyzed the
association of copeptin, an established surrogate for AVP, with parameters of renal function andmorphology in a
multicentric population-based cohort. Participants from families of European ancestry were randomly selected in
three Swiss cities. We used linear multilevel regression analysis to explore the association of copeptin with renal
function parameters as well as kidney length and the presence of simple renal cysts assessed by ultrasound
examination. Copeptin levels were log-transformed. The 529women and 481men hadmedian copeptin levels of
3.0 and 5.2 pmol/L, respectively (P,0.001). In multivariable analyses, the copeptin level was associated inversely
with eGFR (b=22.1; 95%conﬁdence interval [95%CI],23.3 to20.8;P=0.002) and kidney length (b=21.2; 95%CI,
21.9 to20.4;P=0.003) butpositivelywith24-hoururinary albuminexcretion (b=0.11; 95%CI, 0.01 to0.20;P=0.03)
and urine osmolality (b=0.08; 95% CI, 0.05 to 0.10; P,0.001). A positive association was found between the
copeptin level and the presence of renal cysts (odds ratio, 1.6; 95% CI, 1.1 to 2.4; P=0.02). These results
suggest that AVP has a pleiotropic role in renal function andmay favor the development of simple renal cysts.
J Am Soc Nephrol 26: ccc–ccc, 2014. doi: 10.1681/ASN.2014030260
The antidiuretic hormone arginine vasopressin (AVP)
plays an essential role in osmoregulation by facilitating
water transport in the collecting duct.1 This effect is
mediated by the stimulation of the G protein–coupled
vasopressin V2 receptor (V2R), increasing cAMP
levels and leading to a transient increase in osmotic
water transport across theprincipal cells.2 Furthermore,
it was recently demonstrated that V2Rs are also ex-
pressed in the thick ascending limb of the human
kidney.3,4 In addition to the V2R, AVP acts on the
V1a receptor (Ca2+ as second messenger), which is
distributed in the endothelial cells lining systemic
and renal blood vessels and capillaries (including
vasa recta), as well as the glomerulus, the macula
densa, themedullary interstitial cells, and the cortical
collecting duct.5–7 Of note, V1a receptors seem to
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antagonize V2 effects on urinary concentration by activating
prostaglandin synthesis, but higher levels of AVP are required to
activate those receptors.7 The functional relevance of the complex
expression pattern of V1a receptors and V2Rs remains debated.
Experimental studies using the Brattleboro rat, which is genet-
ically deﬁcient in AVP, as well as pharmacologic inhibition
based on V2R-speciﬁc or V1a/V2R antagonists showed a de-
crease in kidney disease progression, kidney hypertrophy, and
proteinuria.8–10 Abnormal AVP signaling and increased cAMP
levels are also involved in renal cyst formation in various rodent
models of autosomal dominant polycystic kidney disease
(ADPKD), as evidenced by the protective effect of high water
intake, selective V2R antagonists, and genetic deletion of AVP
in such models.9,11,12 The role of AVP/V2R signaling on
cystogenesis was recently conﬁrmed by a large randomized,
double-blind placebo-controlled trial testing the effect of a
V2R antagonist in patients with ADPKD.13 Taken together, these
studies suggest that AVP exerts pleiotropic effects on the kidney,
beyond regulation of water balance.Whether such effects can be
detected in the general population remains unknown.
Thus far, population-based studies addressing the role of AVP
were limited by technical issues related to AVPmeasurement,14–16
such as high preanalytical instability,16,17 low sensitivity linked
to competitive assay,18 and a long turn-around time (4–10 days).
AVP is a small nonapeptide thatmust be isolated fromplasma by
chromatography and further concentrated before the assay,
which notoriously complicates the analytical procedure.14,19
Even with RIAs, AVP remains difﬁcult to measure: Its plasma
t1/2 is short, it is not stable ex vivo, and it interferes with plasma
components or factors such as heparin.15,20,21 In addition, storage
at 220°C and freeze-thaw cycles result in a decline of plasma
AVP levels over time. These issues have limited the use of AVP
measurement in clinical practice, explaining the small number
of cohort studies. Copeptin (also named CT-proAVP) is a peptide
derived fromthecleavageof theprecursorofAVP(provasopressin),
produced in an equimolar ratio.17 Copeptin is strongly correlated
toAVPover a large range of plasma levels and has the same kinetics
in response to changes inplasmaosmolality orduringhemorrhagic
shock.18,22–26 Furthermore, copeptin has a longer t1/2 than AVP, is
stable at room temperature, and does not need extraction nor
special sample handling procedures. For these reasons, copeptin
is now considered as a robust surrogate for AVP, overcoming the
technical problems related to AVP dosage.17
In this study, we investigated the potential link of copeptin
with renal function parameters, including eGFR, urine albumin
excretion and urine osmolality, the morphology of the kidney,
and the presence of simple renal cysts, in a large, multicentric
population-based cohort.
RESULTS
From December 2009 to March 2013, 1128 participants were
included in the SwissKidney Project onGenes inHypertension
(SKIPOGH)study.Renal ultrasonographymeasurementswere
obtained in 1125 participants (99.7%). We excluded 6 (0.5%)
participants because of missing copeptin measures and 111
(9.8%) with incomplete data for the outcomes of interest or
covariables, mainly urinary ones. Another participant was
excluded because of a fortuitous diagnosis of typical ADPKD
on ultrasonography. Finally, we included 1010 participants in
these analyses.
The characteristics of the 529 women and 481 men are
presented in Table 1. Men had higher plasma copeptin levels
than women. They also had higher body mass index (BMI),
higher BP, eGFR, triglycerides, urinary osmolality values, and
24-hour osmolar excretion, as well as a higher prevalence of
other cardiovascular risk factors such as smoking, treated
hypertension, and diabetes.
Ultrasonography examination revealed that men had sig-
niﬁcantly larger kidneys andmore cysts thanwomen.Only one
participant hadmissing information on kidney length because
of a horseshoe kidney. The prevalence of renal simple cysts was
12% (n=121) in the studied population, and increased with
age: 2.4%, 12.3%, and 24.6% for those aged ,40, 40–59, and
$60 years, respectively. A signiﬁcantly higher prevalence of
cysts was observed inmen than inwomen in each age category:
3.1% versus 1.7%before 40 years (P=0.39), 16.7% versus 9.1%
at 40–59 (P=0.03), and 31.5% versus 18.3% after 60 years
(P=0.01). The median of the largest diameter measured in
the biggest cyst was 17.0 mm (interquartile range [IQR],
10.5–24.8).
In addition to cysts, the presence of kidney stones was
suspected by ultrasonography in 65 participants (6.4%), without
signiﬁcant differences between men and women (7.5% versus
5.5%; P=0.20).
Association Analyses
In univariate analyses, participants aged.60 years had higher
median copeptin levels than younger participants (4.4 pmol/L
[IQR, 3.0–6.8] versus 3.8 pmol/L [2.6–5.7]; P,0.001), and
copeptin was higher in participants with higher BMI (BMI
$30 kg/m2=5.1 pmol/L [3.4–7.9] versus BMI 25–29.9 kg/m2=
4.4 pmol/L [3.2–6.5] versus BMI ,25 kg/m2=3.4 pmol/L
[2.4–5.2]; P for trend, P,0.001). Copeptin levels were also
signiﬁcantly higher in smokers than in nonsmokers
(4.4 pmol/L [IQR, 2.9–6.6] versus 3.8 pmol/L [2.6–5.7];
P=0.003) and in patients with diabetes than in patients without
diabetes (6.1 pmol/L [4.0–9.7] versus 3.9 pmol/L [2.7–5.7];
P,0.001) or CKD (5.1 pmol/L [3.8–10.4] versus 3.9 pmol/L
[2.7–5.9]; P,0.001). Participants with a pathologic 24-hour
albumin-to-creatinine ratio (ACR) also presented higher copeptin
levels (5.0 pmol/L [IQR, 3.2–8.7] versus 3.9 pmol/L [2.7–5.8];
P,0.001). Copeptin levels were higher in individuals taking
diuretics than in those not taking them (4.5 pmol/L [IQR, 3.3–7.9]
p versus 3.9 pmol/L [2.7–5.9]; P=0.03) but not when all hyper-
tension treatment were considered (4.4 [2.8–6.6] versus 3.9
[2.7–5.8]; P=0.10).
Copeptin levels were positively associated with both the
presence of simple cysts (4.8 pmol/L [IQR, 3.6–7.9] versus
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3.8 pmol/L [2.6–5.7]; P,0.001) and the number of cysts in the
kidneys (Figure 1A). Kidney size increased with the number of
cysts (Figure 1B). Participants with numerous kidney cysts
were signiﬁcantly older and presented higher systolic BP and
24-hour urinary albumin excretion and lower eGFR compared
with those with only one cyst or without cysts (Table 2). The
association of cysts with copeptin was stronger in younger
participants (,61 years; odds ratio [OR], 2.27; 95% conﬁ-
dence interval [95% CI], 1.29 to 3.00; P=0.01) than in older
participants ($61 years; OR, 1.26; 95% CI, 0.70 to 2.15;
P=0.40). These associations remained similar upon adjustment
for eGFR. A higher urinary osmolality was observed in partic-
ipants with numerous kidney cysts (P=0.03).
Compared with participants without evidence of kidney
stones, thosewith suspected stones hadhighermedian24-hour
urine osmolality (569.0 mOsm/kg H2O [IQR, 385.7–795.2]
versus 489.3 mOsm/kg H2O [355.5–646.5]; P=0.02), a lower
urinary ﬂow rate (0.9 ml/min [0.7–1.3] versus 1.1 ml/min
[0.8–1.5]; P=0.02), and higher copeptin levels (4.9 pmol/L
[3.0–8.4] versus 3.9 pmol/L [2.7–5.8]; P=0.01).
We found a linear association between copeptin and most
of the continuous variables in Table 1. Because sex was a
major confounder for many of the associations, we presented
univariate correlations separately for men and women (Table 3).
Only BMI, height, eGFR, 24-hour urinary ﬂow rate, and urinary
osmolality had a signiﬁcant associationwith copeptin inmen and
women.
Theassociationof copeptinwith eGFR,24-hoururine albumin
excretion, 24-hour urine osmolality, and kidney length ad-
justed for age, sex, and center is presented graphically in Figure 2.
Table 4 describes the b coefﬁcients, ORs, and 95% CIs for the
associations between copeptin levels and these variables of in-
terest (dependent variables) in different multivariate models
progressively integrating other covariates. Because all of the
models are adjusted for sex, results are presented altogether
for men and women. In all models, urinary albumin excretion
and urinary osmolality were positively associated with adjusted
copeptin levels. On the contrary, eGFR and kidney length pre-
sented an inverse association with adjusted copeptin levels.
Adding mean BP as a covariate to the last model did not change
these associations. The inverse association with kidney length
was maintained even when the model was adjusted for body
height instead of BMI, although theb coefﬁcients were smaller.
Of note, we observed that kidney length remained associated
with eGFR (b=0.16; 95% CI, 0.12 to 0.20; P,0.001), urine
osmolality (b=0.004; 95% CI, 0.001 to 0.01; P=0.03), and
Table 1. Characteristics of the participants according to sex (N=1010)
Characteristic Women (n=529) Men (n=481) P Value
Age (yr) 47.9617.3 46.5617.8 0.20
BMI (kg body wt/m2) 24.264.7 25.964.2 ,0.001
Height (cm) 164.866.5 177.666.9 ,0.001
Systolic BP (mmHg) 115.3617.5 120.9615.5 ,0.001
Diastolic (mmHg) 73.669.6 77.969.1 ,0.001
Copeptin (pmol/L) 3.0 (2.2–4.2) 5.2 (3.7–7.8) ,0.001
eGFR (ml/min per 1.73 m2) 94.7617.2 98.5618.4 0.001
Plasma sodium (mmol/L) 140.362.6 140.362.5 0.88
Estimated plasma osmolarity (mOsm/L) 288.765.2 288.865.0 0.68
Plasma triglycerides (mmol/L) 0.8 (0.6–1.1) 1.0 (0.7–1.4) ,0.001
24-h urine ﬂow rate (ml/min) 1.2 (0.8–1.5) 1.1 (0.8–1.5) 0.17
24-h urine sodium excretion (mmol) 117.5(88.3–150.5) 158.2(121.6–198.4) ,0.001
24-h urine osmolality (mOsm/kg of H2O) 417 (314–563) 570 (430–773) ,0.001
24-h urine creatinine excretion (mg/kg of body wt) 18.1 (14.7–20.8) 22.1 (19.0–25.0) ,0.001
24-h urine albumin excretion (mg) 5.8 (3.8–10.1) 6.0 (3.7–10.6) 0.52
24-h osmolar excretion (mOsm) 669.4 (560.1–800.7) 888.9 (735.7–1047.6) ,0.001
Hypertension treatment (yes) 66 (12.5) 90 (18.7) 0.01
Diabetes (yes) 15 (2.8) 34 (7.1) 0.002
Smoking (yes) 103 (19.5) 137 (28.5) 0.001
CKD (yes) 16 (3.0) 16 (3.3) 0.78
Albuminuria (yes)a 22 (4.2) 38 (7.9) 0.01
Kidney length (mm) 107.067.9 113.768.2 ,0.001
Cysts 48 (9.1) 73 (15.2) 0.003
Number of cysts
None 481 (90.6) 408 (85.0) 0.003
1 38 (7.2) 47 (9.8)
$2 10(1.9) 26 (5.6)
Continuous variables are expressed as the mean6SD or median and IQR (25th–75th percentiles) as appropriate. Categorical variables are expressed as n (%). CKD
was deﬁned as an eGFR,60 ml/min per 1.73 m2. eGFR was calculated with the CKD-EPI equation. Plasma osmolarity was calculated as 23(Na+K). The 24-hour
osmolar excretion was calculated as urine osmolality324-hour urine volume.
aPresence of albuminuria was deﬁned as urinary ACR$25 mg/mg in women and $17 mg/mg in men.
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24-hour osmolar excretion (b=0.01; 95% CI, 0.003 to 0.01;
P,0.001) beyond the fully adjusted model 3. These associations
were linear.
We also looked at the association between copeptin and the
presenceofCKD(n=32)oralbuminuria(n=60)usingdichotomized
eGFR and sex-speciﬁc cutoffs for ACR. In univariate analyses,
the odds of having CKD or pathologic ACRwith higher levels of
copeptin were 2.86 (95% CI, 1.65 to 4.98; P,0.001) and 2.08
(95% CI, 1.39 to 3.11; P,0.001), respectively. In the models
adjusting for sex, age, and center, copeptin remained associated
with CKD (OR, 2.82; 95% CI, 1.45 to 5.50; P=0.002) and ACR
(OR, 1.70; 95% CI, 1.08 to 2.68; P=0.02).
Copeptinwaspositively associatedwith thepresenceof cysts
(Table 4). Even after adjusting for age, sex, and center, partic-
ipants with higher copeptin levels had a higher probability of
having renal cysts (Figure 3). The association remained signif-
icant when adjusting for kidney size and urine concentrating
ability. As described in the univariate analyses, the association
was stronger in younger participants than in older ones, even
when adjusting for age, sex, center, and eGFR. Of note, the
largest diameter of the biggest cyst measured, used as a surro-
gate of cyst size, was not associatedwith copeptin levels neither
in univariate nor in any of the multivariable models (data not
shown).
The association of kidney stones with copeptin observed in
univariate analyses was less signiﬁcant when adjusting for age,
sex, and center (OR, 1.62; 95%CI, 1.02 to 2.58; P=0.04) andwas
no longer statistically signiﬁcant upon further adjustments.
Sensitivity Analyses
Analyses repeated after winsorizing copeptin values led to
similar results. We also obtained similar results after excluding
participants with suspected inaccurate urine collection (n=6),
as deﬁned in the ConciseMethods.We obtained similar results
for the association of renal size with copeptin after excluding
ﬁve participants with a single kidney. Sensitivity analyses in-
cluding only participants having a kidney length within the
normal range of 90–120mm (n=868) led to similar signiﬁcant
associations, although the b coefﬁcients were smaller, as ex-
pected. Excluding participants with renal cysts did not change
the association of eGFR, urinary osmolality, and kidney length
with copeptin, but the association with albuminuria was no
longer signiﬁcant in any of the models.
Heritability estimates (6SEM) for copeptin levels were
34.7% (6.1%; P,0.001) without a sibship component and
32.7% (5.5%; P,0.001) with a sibship component.
DISCUSSION
Several lines of evidence have demonstrated a link between
AVP, renal cyst development, and total kidney volume in rodent
models and patients with ADPKD.27 However, to the best of
our knowledge, the potential association of AVP with the pres-
ence of simple renal cysts, or with kidney size, has not been
investigated in normal individuals without ADPKD. For the
Figure 1. Association of the number of renal cyst with copeptin levels
and kidney length. (A) Unadjusted analysis. (B) Analysis adjusted for
age, sex, center, and body height. Bars represent the SEM.
Table 2. Characteristics of participants according to the number of cysts
Variable No Cysts (n=889) 1 Cyst (n=85) ‡2 Cysts (n=36) P for Trend
Age (yr) 45.4617.1 58.0614.6 67.5611.0 ,0.001
Systolic BP (mmHg) 116.8616.4 125.5617.3 130.8616.8 ,0.001
eGFR (ml/min per 1.73 m2) 98.0617.3 88.8618.8 79.8618.7 ,0.001
24-h urine osmolality (mOsm/kg of H2O) 486 (357–647) 527 (338–740) 602 (419–723) 0.03
Urine albumin excretion (mg/24 h) 5.7 (3.6–9.7) 8.4 (3.9–14.5) 10.0 (5.5–14.9) ,0.001
Kidney length (mm) 109.968.5 110.869.0 114.5611.5 0.01
Data are expressed as the mean6SD or the median and IQR (25th–75th percentiles).
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ﬁrst time, this cross-sectional study describes the association
of plasma copeptin levels with renal function, kidney length, and
renal simple cysts in a large, multicentric population-based
cohort. We demonstrate that higher copeptin levels are associ-
ated with lower eGFR, higher urinary albumin excretion, higher
urinary osmolality, smaller kidney length,
and the presence of simple renal cysts even
after multiple adjustments.
Kidneylengthmeasuredbyultrasonography
is an easy and reproducible way of estimating
kidney size, and is generally considered as a
proxy of renalmass.28,29 In previous studies,
kidney length correlated positively with
eGFR in living kidney donors and the gen-
eral population.28,30 Conversely, a shorter
kidney length has been associated with
higher BP and albuminuria in an Australian
community.31 Accordingly, it is tempting to
hypothesize that the negative association
between copeptin levels and kidney length,
persisting even after adjusting for osmolar
excretion, may reﬂect an inﬂuence of the
later parameter on urinary concentrating
ability. The association of a shorter kidney
length with lower urinary concentrating
ability is in fact supported by our results
showing a positive correlation between kid-
ney length and eGFR and urine osmolality
even after adjustment for several covariates.
It must be noted that the negative correla-
tion between copeptin and kidney length is
observed in participants without kidney
cysts and in participants with kidney length
within the normal range (90–120 mm).
Taken together, these data suggest that the
urinary concentrating ability determined by
kidney length is probably the main factor
driving AVP/copeptin levels in a normal
population and support the hypothesis
that kidney length might somehow reﬂect
kidney function.
The association between copeptin levels
and the presence and number of simple
cysts in a general population is a novel
ﬁnding. We show that this association is
independent of age, renal function, kidney
length, and urinary concentrating ability.
Thus far, AVP/copeptin levels have only
been considered in patients with ADPKD.
In ADPKD, increased levels of AVP con-
tribute to the abnormal, cAMP-mediated
signaling in collecting duct cells, promoting
cyst development by several mechanisms.27
The positive association of copeptin levels
with total kidney volume in ADPKD also
reﬂects the cystic disruption of the medulla, leading to the
defective urinary concentrating ability that is consistently ob-
served early in the disease.19,27 By contrast, our results suggest
that AVP may also play a role in the formation of simple renal
cysts in the general population.
Table 3. Associations between copeptin and continuous variables according to
sex
Variable
Women (n=529) Men (n=481)
Correlation P Value Correlation P Value
Age (yr) 0.12 0.01 0.07 0.13
BMI (kg of body wt/m2) 0.24 ,0.001 0.10 0.02
Height (cm) 20.13 0.002 20.19 ,0.001
Systolic BP (mmHg) 0.16 ,0.001 0.07 0.14
Diastolic BP (mmHg) 0.10 0.02 20.02 0.66
eGFR (ml/min per 1.73 m2) 20.12 0.01 20.12 0.01
Plasma sodium (mmol/L) 0.01 0.79 0.08 0.08
Estimated plasma osmolarity (mOsm/L) 0.02 0.73 0.08 0.09
Plasma triglycerides (mmol/L) 0.03 0.53 20.01 0.88
24-h urine ﬂow rate (ml/min) 20.38 ,0.001 20.41 ,0.001
24-h urine sodium excretion (mmol) 0.001 0.98 20.02 0.62
24-h urine osmolality (mOsm/kg H2O) 0.37 ,0.001 0.44 ,0.001
24-h urine creatinine excretion (mg/kg
of body wt)
20.16 ,0.001 20.02 0.67
24-h urine albumin excretion (mg) 0.04 0.38 0.13 0.004
24-h osmolar excretion (mOsm) 20.03 0.54 20.01 0.81
Kidney length (mm) 20.06 0.20 20.12 0.01
Data are Pearson’s correlation coefﬁcients and corresponding P values. Copeptin, triglycerides, urine
ﬂow rate, 24-hour urine osmolality, and albumin excretion were log-transformed. Urine sodium and
creatinine excretion were square-root transformed. Plasma osmolarity was calculated as 23(Na+K).
The 24-hour osmolar excretion was calculated as urine osmolality324-hour urine volume.
Figure 2. Association of copeptin with CKD-EPI, 24-hour urine albumin excretion, 24-hour
measured osmolality, and kidney length. A–D are adjusted for age, sex, and center.
Shaded areas represent the 95% CI.
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Theprevalenceof simple cysts tends to increasewith age and
may reﬂect kidney aging.32,33 The 12% prevalence of cysts
detected by ultrasonography in our series, as well as the in-
creased risk with age and the sex difference are in line with
previous reports.32,34,35 The mechanisms leading to the for-
mation of simple cysts in the kidney remain largely unknown.
By deﬁnition, these cysts are acquired and fundamentally
distinct from the ADPKD cysts that appear in utero as the
result of complex genetic mechanisms.36 Simple cysts likely
originate from the distal convoluted or collecting duct and are
thought to arise from renal tubular diverticula, or from tubular
cell hyperplasia secondary to nephron loss.37–39 Previous studies
in healthy subjects described associations between hyperten-
sion and benign renal cysts.40–42 In a cross-sectional analysis of
hospitalized patients without overt renal disease undergoing an
abdominal computed tomography scan, the presence of cysts
was associated with a reduced renal function estimated by
creatinine clearance.33 In our cohort, the association between
copeptin and cysts was independent of age, hypertension, kidney
function, and even urinary concentration, suggesting a distinct
pathway. If elevated copeptin was simply a consequence of
kidney damage rather than being causally involved in cyst for-
mation, the association of copeptinwith cysts should be stronger
in older people who have accumulated kidney damage over time
and have lower eGFR, and would decrease upon adjustment for
eGFR. By contrast, stratiﬁed analyses revealed that the associa-
tion of copeptin with renal cysts was stronger in younger partic-
ipants than in older participants in this study. The mechanisms
linking the potential association of AVP with simple cyst forma-
tion, as well as the clinical relevance of such association, will
require further investigations.
Our results conﬁrm the previously reported negative associ-
ation between copeptin levels and eGFR. This association has
been observed in prospective studies involving patients with
ADPKD as well as patients with a renal transplant and patients
with diabetes.43–48 Only two studies have used a population-
based sample to test the hypothesis that AVP might be involved
in the development of albuminuria. In the Prevention of Renal
and Vascular Endstage Disease (PREVEND) study, which in-
cludes 7593 nondiabetic participants with an urinary albumin
concentration $10 mg/L, circulating copeptin was positively
associated with albuminuria and negatively with renal function
in a cross-sectional analysis.49 In 2064 participants from the
Table 4. Multilevel multivariable regression analyses showing associations of GFR, 24-hour urine albumin excretion, urine
osmolality, kidney length, and the presence of renal cysts with log-transformed copeptin levels
Dependent Variable
Model 1 Model 2 Model 3
b (95% CI) P Value b (95% CI) P Value b (95% CI) P Value
eGFR (ml/min per 1.73 m2) 22.06 (23.33 to 20.79) 0.001 22.12 (23.41 to 20.84) 0.001 22.05 (23.33 to 20.76) 0.002
Urine albumin excretion (mg/24 h)a 0.12 (0.03 to 0.22) 0.01 0.10 (0.001 to 0.19) 0.05 0.11 (0.01 to 0.20) 0.03
24-h urine osmolality (mOsm/kg)b 0.28 (0.24 to 0.32) ,0.001 0.28 (0.24 to 0.32) ,0.001 0.08 (0.05 to 0.10) ,0.001
Kidney length (mm)
Adjusted for BMI 21.42 (22.26 to 20.57) 0.001 21.70 (22.52 to 20.89) ,0.001 21.62 (22.43 to 20.81) ,0.001
Adjusted for body height and
body wt
21.01 (21.83 to 20.19) 0.02 21.22 (21.99 to 20.45) 0.002 21.16 (21.93 to 20.39) 0.003
Renal cysts (present, n=121)c 1.62 (1.11 to 2.38) 0.01 1.55 (1.05 to 2.31) 0.03 1.61 (1.08 to 2.41) 0.02
Model 1 is adjusted for age, sex, and center.Model 2 is adjusted formodel 1 plus diabetes, hypertension treatment, triglycerides, smoking, BMI, and eGFR.Model 3
is adjusted for model 2 plus estimated plasma osmolarity, 24-hour urine creatinine excretion, and 24-hour osmolar excretion.
aFor 24-hour urine albumin excretion analyses, all models were adjusted for 24-hour urine creatinine excretion. Models 2 and 3 were adjusted for fasting glucose
instead of diabetes. Urinary albumin was log-transformed.
bThe 24-hour urinary osmolality was log-transformed and model 3 included urine ﬂow rate alone instead of osmolar excretion.
cORs are presented for renal cysts.
Figure 3. Higher copeptin levels are associated with higher prob-
ability of having cysts adjusted for age, sex, and center.
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MalmöDiet and Cancer study, baseline circulating copeptinwas
associatedwith the incidence of diabetes, obesity, and albuminuria
after 16 years of follow-up.50 In healthy volunteers, eGFR was also
found to be an independent predictor of copeptin levels.51 Some
studies have measured GFR using iothalamate, 99mTc-DTPA, or
inulin clearance.43–46 Other studies estimated eGFR using the
Modiﬁcation of Diet in Renal Disease formula or cystatin C but
not the Chronic Kidney Disease Epidemiology Collaboration
(CKD-EPI) equation, which is known to be the most reliable
formula.47,49–51 In our study, we observe an inverse linear asso-
ciation with copeptin levels even in participants with normal
eGFR and conﬁrm an almost 3 times increased odds of CKD in
patients with higher copeptin levels.
Several hypotheses could explain the association of AVP/
copeptin levels with renal function. It could be that copeptin
(molecular mass, 5 kD) is cleared by the kidneys and accumulates
in the circulation when kidney function decreases. However,
longitudinal studies inhumanshave shown that plasma copeptin
levels increase before eGFR decreases.44,45,47,48 A decreased uri-
nary concentrating capacity precedes the decrease of GFR in
numerous kidney diseases. Increased copeptin levels might
be a marker of this early phase of renal dysfunction. From an
adaptive response, increased AVP/copeptin levels might become
maladaptive and enhance CKD progression. Water ingestion,
which readily decreases circulating AVP/copeptin levels, may
modify CKD progression.52 Studies in the 5/6 nephrectomized
rat model suggested that increased water intake decreases circu-
lating AVP levels and slows down the progression of kidney
disease.53 Taken together, these data suggest that high levels of
AVP may be deleterious for kidney function, either by a direct
hemodynamic effect through V1a vascular receptors or through
V2 tubular receptors.
Our results also suggest an association between copeptin
levels and albuminuria (24-hour collection) in the general
population. These data support earlier reports in ADPKD,43
and the general population, although the signiﬁcance levels were
lower in our study.49,50 This can be due to the higher number of
patients in those studies, the fact that thePREVENDstudyused a
cutoff of 10 mg/L albuminuria for inclusion, and the Malmo
study analyzed ACR in spot urine instead of 24-hour urine col-
lection. Previous studies have shown an association between
albuminuria and urinary concentrating ability in diabetic
rats,54 as well as in healthy rats and humans,55 suggesting that
increased AVP has a proalbuminuric effect. Because only V2
antagonists decrease proteinuria in animal models, one can
hypothesize that albuminuria is somehow related to tubular
V2Rs.9,54 Whether AVP antagonists can reduce albuminuria in
humans is actually unknown and should be assessed in clinical
studies. Post hoc analysis from the TEMPO 3.4 trial, presented at
the 2013 American Society of Nephrology Annual Meeting by
Gansevoort et al. shows that tolvaptan reduces albuminuria in
patients with ADPKD.56 Our results raise the question of
whether targeting AVP to decrease kidney disease progression
could be an option in patients with kidney diseases other than
ADPKD.
Because kidney stones are associated with concentrated
urines and lower urinary ﬂow rate, we explored their potential
association with copeptin in our sample. The observed pos-
itive association was no longer statistically signiﬁcant upon
multivariable adjustment. Although we found a prevalence
of stones similar to a previous study in a very selected popula-
tion of kidney donors,57 assessment by ultrasonography is
associated with underdetection of stones compared with
computed tomography.57,58 The administration of vasopressin
antagonist in order to reduce cystine stone formation was de-
scribed in a case report.59 To the best of our knowledge, there is
no evidence for the association of AVPor copeptin with kidney
stones. Thus, further studies are needed to determine whether
AVP or copeptin are associated with kidney stones.
This study has some limitations. Its cross-sectional nature
limits causal inferences: We see associations but we cannot
conﬁrm the direction of these associations or the causality.
However, because the heritability integrates the genetic pattern
that occurs before the disease, this suggests causality. We only
included participants of European ancestry and therefore our
ﬁndingsmight not be valid for other populations. Therewas no
difference in terms of age and sex between the participants and
the sample from the general population from which it was
drawn, and it is unlikely that this would induce spurious
associations as strong and consistent as the ones we detected.
Although renal ultrasonography is a reliable tool for estimating
kidney length, it is not as sensitive as computed tomography or
magnetic resonance imaging to detect renal cysts, and very
small cysts might have been missed.60 The signiﬁcance of very
small cysts is unknown but we may have underestimated the
association between copeptin and renal cysts. Given the cross-
sectional design of our study, whether high copeptin levels
are the consequence rather than the cause of simple renal
cysts remains uncertain. Only long-term follow-up studies
will be able to conﬁrm whether individuals with higher base-
line copeptin levels are at risk of having shorter kidneys and
more cysts or the reverse. Finally, the positive association of
copeptin with urinary osmolality is similar to that reported
for AVP. Although the physiologic regulation of copeptin
release seems to be similar than that of AVP,26 we cannot
exclude that other regulatory factors are involved. In addition,
it is unknown whether copeptin acts on the same receptors as
AVP. Copeptin is currently the most widely accepted surrogate
marker for AVP despite the fact that these peptides are different
entities.
In conclusion, we show a novel association of circulating
copeptinwith kidney length and the prevalence of simple renal
cysts in a large multicentric population-based study. We also
conﬁrm that higher copeptin is associated with increasing
urine osmolality, similar to AVP, andwith lower renal function
and higher 24-hour urine albumin excretion.
These results suggest that copeptin is a marker of renal
morphology and function in the general population. By
extension, they give new insights into the pleiotropic role of
AVP, including the formation of simple renal cysts.
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CONCISE METHODS
Study Population
SKIPOGH is a family-based cross-sectional study exploring the role
of genes and kidney hemodynamics in BP regulation and kidney
function in the general population. It is nested in the European
Project on Genes in Hypertension study and shares the same validated
protocol. A detailed description of the methods was provided
elsewhere and is brieﬂy described here.61
From December 2009 to March 2013, adult participants were
recruited in two regions (Berne and Geneva) and one city (Lausanne)
of Switzerland. A random sample of the inhabitants was drawn using
different strategies. Inclusion criteria were as follows: (1) having a
minimum age of 18 years; (2) being of European ancestry; (3) having
at least one and ideally three ﬁrst-degree family members willing to
participate; and (4) providing a written informed consent. Pregnant
or breastfeeding women were not included. The SKIPOGH study
adhered to the Declaration of Helsinki and was approved by the
institutional ethical committees of each participating university
hospital.
Measurement and Deﬁnitions
Participants were seen in the morning after an overnight fast. In each
center, the same experienced operator performed renal grayscale and
Doppler ultrasonography according to a standardized procedure.28
Brieﬂy, the renal length of each kidney was measured in the supine
position or left/right decubitus if needed. The mean of three optimal
measures was reported. Because there was no difference between the
left and right kidneys, the mean length of both kidneys was used for
the analysis. Benign renal cysts were diagnosed based on known criteria:
echolucent structure, round or oval in shape with a thin wall, well
deﬁned and smooth contours with a sharp demarcated posterior wall,
no calciﬁcation, no septa, and noDoppler signal within the cyst.62 The
number of cysts and the maximal diameter of the biggest cyst were
reported. We also reported the presence of kidney stones suspected on
the same ultrasound examination.
Fasting blood venous samples were drawn after the participants
had been lying in a supine position for at least 30 minutes. A 24-hour
urine sample was collected separately for day and night, and oral and
written instructions were given on how to perform the urinary
collection. Blood glucose, lipid proﬁle, and renal function tests as well
as serum and urinary electrolytes were analyzed by standard clinical
laboratory methods in each center. Creatinine was measured using
IDMS-traceable Jaffe kinetic compensated methods. Urine albumin
wasmeasuredquantitatively by immunonephelometry on aBNProspec
automated analyzer (Siemens Healthcare Diagnostics, Marburg,
Germany) or immunoturbidimetry (Roche/Hitachi Modular P). In
addition to the continuous urinary albumin excretion in mg per
24 hours, we used urinary creatinine and albumin to calculate the ACR
in milligrams per millimole. The correlation between albumin
excretion and ACR was strongly positive (r=0.93; P,0.001). Urinary
osmolality was measured centrally using an Advanced Osmometer
(Advanced Instruments, Norwood, MA) based on the freezing-point
depression. A control (Clinitrol 290) and a set of calibration standards
(50, 850, and 2000 mOsm/kg) were used before running each sample
batch. The coefﬁcient of variability was 0.19% in urine. The 24-hour
osmolar excretion was calculated as the product of 24-hour urine
osmolality and 24-hour urine volume. Copeptin was measured on
280° frozenEDTA-plasma samples in a batch using a previously described
sandwich immunoluminometric assay (Thermo Fisher Scientiﬁc
CT-proAVP KRYPTOR; BRAHMS GmbH, Hennigsdorf, Germany).17
The lower detection limit was 0.9 pmol/L and the functional assay sen-
sitivity (20% interassay coefﬁcient of variation) was ,2 pmol/L. Esti-
mated plasma osmolarity was calculated as 23(plasma sodium+plasma
potassium).
Participants ﬁlled out a questionnaire at home, which requested
information on current and past medical history, medication, and
habits (nutrition, smoking, and alcohol).
Diabetes was deﬁned as reported, treated, or fasting glycemia
$7 mmol/L. In this analysis, antihypertensive treatment was used as
a covariate to account forhypertension.TheCKD-EPI formulawasused to
estimate the eGFR.63 CKD was deﬁned as present for eGFR,60 ml/min
per 1.73m2. The presence of albuminuria was deﬁned using published
sex-speciﬁc cut-points: whenever ACR (multiplied by 8.84) was
$25 mg/mg in women and $17 mg/mg in men.64
Statistical Analyses
All of the continuous variables with normal distribution are expressed
as the mean6SD and as the median (IQR) in case of skewed distribu-
tion. Categorical variables are expressed as numbers and frequencies.
The normality of the distribution of each continuous variable was
assessed graphically. Serum triglycerides, copeptin, 24-hour urinary
albumin excretion, and urine osmolality levels were log-transformed
for statistical analyses. Finally, t tests and chi-squared tests were per-
formed to compare baseline characteristics for continuous and cate-
gorical variables, respectively.
Association Analyses
We ﬁrst conducted univariate analyses to look for associations
between copeptin and the outcomes of interest (CKD-EPI, 24-hour
urinary albumin excretion, 24-hour urinary osmolality, renal length,
and presence of CKD, cysts, or albuminuria) and the other covariates.
We calculated Pearson’s correlation coefﬁcients for continuous vari-
ables (transformed whenever needed) and used the t test or trend test
for categorical variables.
We applied differentmultivariablemixed linear regressionmodels
to determine the independent association of copeptinwith CKD-EPI,
albuminuria, urinary osmolality, and renal length, while taking familial
correlation into account. In the ﬁrstmodel, we adjusted for sex, age, and
center. In the secondmodel, we additionally adjusted for cardiovascular
risk factors (diabetes, hypertension treatment, triglycerides, smoking,
BMI, and CKD-EPI). In the third model, we adjusted for estimated
plasma osmolarity, 24-hour osmolar excretion, and urinary creatinine
excretion. For 24-hour urine osmolality, we adjusted for urinary ﬂow
rate instead of osmolar excretion. Because hypertension treatment was
included as a covariate in themodels, we did not adjust for BP. Although
the results are not shown, we systematically checked that adding BP did
not change the associations.
For the continuous albuminuria analysis, 24-hour urinary creatinine
excretion (in milligrams per kilogram) was added as a covariate in all
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models to account for the quality of urine collection. For kidney length,
we ﬁrst generated a model including BMI as for the other outcomes of
interest. Because body height is amajor determinant of kidney length,28
we then repeated the models adjusting for body height and weight
instead of BMI. Results of all linear regression analyses are presented
as b coefﬁcients and their 95% CIs.
Linearity between log-transformed copeptin and the outcomes of
interest was tested in three ways: (1) graphically, (2) using sex-speciﬁc
tertiles of copeptin, and (3) including the square of the log-transformed
copeptin as a covariate in the models to conﬁrm the absence of a
quadratic association.
Wealso looked into the associationof copeptinwith thepresenceof
cysts, CKD, or albuminuria (ACR) using mixed logistic regression
taking familial correlations into account. Sex, age, and center were
used as covariates. For CKD and dichotomized albuminuria, we did
not conduct additional adjustment models because of the small
number of events. For the association of copeptin with cysts, we also
stratiﬁed the analyses by age, using a cutoff of 61 years to obtain two
groups with the same number of cysts.
Interactionof copeptinwith sex, diabetes, smoking, and centerwas
tested for their effects on continuous outcomes of interest (CKD-EPI,
24-hour urine albumin, 24-hour urine osmolality, and renal length)
but not for the categorical ones (presence of albuminuria and CKD),
because of the small number of events. Interactionwas found between
diabetes and copeptin when looking at the association with continuous
albuminuria (P,0.001), but stratiﬁed multivariate analyses could not
be conducted because of the small number of participants with diabetes
(n=49). In that case, models 2 and 3 were adjusted for fasting glucose
instead of diabetes, as done in previous studies.49,50
To generate the panels in Figure 2, for each dependent variable
separately, we ﬁrst generated adjusted residuals from mixed linear
models, including age, sex, and center as covariates, and then scaled
them by adding the mean of the dependent variable. In Figure 3, we
generated the adjusted predicted probability of cyst at selected levels
of log-transformed copeptin, including age, sex, and center as covariates
in the model, using the margin function in Stata.
Statistical signiﬁcance was considered for a two-sided P,0.05.
Statistical analyses were conducted using STATA 12.0 software (StataCorp,
College Station, TX).
Sensitivity Analyses
We repeated the analyses replacing extreme values of copeptin by
percentiles 99 (18.77) and 1 (1.161) in order to determine the inﬂuence
of outliers (winzorization).
We repeated the analyses excluding participants that could have
inaccurate urine collections deﬁned as a 24-hour volume,300ml or a
24-hour creatinine excretion of ,4 mmol or .25 mmol in women
and ,6 mmol or .30 mmol in men.65
The same multivariate analyses were conducted in participants
without cysts and with kidney length within the normal range (90–
120 mm).
Heritability Analyses
Heritability is a measure of familial resemblance. It is useful in family-
based studies to estimate the role of genes in a speciﬁc phenotype.
Because heritability takes into account the genetic pattern that occurs
before the disease, it gives an argument for causality.
To estimate heritability, we applied a maximum likelihood
approach, as implemented in the ASSOC procedure of the S.A.G.E.
package, as previously described.66 We also estimated heritability in
the presence of an additional sibship component of variance, which
captures both the common environment and a dominance genetic
variance. Heritability estimates are expressed as h2 values with SEM.
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